Zymeworks Inc (ZYME) Stock
Fundamentals
Recent news

SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
ZYME

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
ZYME

JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy
JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy
ZYME

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
ZYME
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.22 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
ZYME

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
ZYME

JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy
JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy
ZYME

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
ZYME

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates
ZYME

Theravance Stock Down 3% After Zymeworks Announces Buyout
Theravance Stock Down 3% After Zymeworks Announces Buyout
ZYME

Zymeworks strikes $929 million deal for Theravance Biopharma
Zymeworks strikes $929 million deal for Theravance Biopharma
ZYME

Zymeworks Q1 Earnings Call Highlights
Zymeworks Q1 Earnings Call Highlights
ZYME

Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
ZYME

Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates
ZYME
About Zymeworks Inc
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Kenneth H. Galbraith C.A. | Chairman of the Board, CEO & President | 1962 |
| Dr. Paul A. Moore Ph.D. | Chief Scientific Officer | 1967 |
| Mr. Scott Platshon B.S. | Executive VP & Chief Business Officer | 1991 |
| Ms. Kristin Stafford CPA | Executive VP & CFO | 1982 |
| Mr. Mark Hollywood | Executive VP & COO | 1969 |
| Ms. Shrinal Inamdar B.Sc. | Vice President of Investor Relations | — |
| Mr. Paul R. Schneider | Executive VP & General Counsel | 1971 |
| Ms. Diana Papove B.Com. | Vice President of Corporate Communications | — |
| Dr. Lindsey Foulkes B.Sc., Ph.D. | Senior Vice President of Corporate Development & Strategy | — |
| Ms. Laura O'Connor | Senior VP & Chief Human Resources Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
8 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +6.2 | -24.1 | -14.1 | -19.0 | ||||||||
| 2022 | -47.6 | -13.9 | -4.9 | -8.3 | -2.2 | -24.1 | +5.4 | +7.9 | -4.9 | +25.1 | +3.6 | +1.7 |
| 2023 | +25.3 | -11.3 | +12.9 | -10.4 | -2.4 | +1.8 | -13.1 | -2.8 | -15.4 | +13.4 | +26.4 | +13.6 |
| 2024 | +4.4 | +9.4 | -15.9 | -13.2 | -3.2 | +0.9 | +21.5 | +16.0 | +8.9 | +10.9 | +6.1 | +1.0 |
| 2025 | -1.2 | -8.8 | -6.5 | +12.0 | -11.3 | +7.8 | +1.2 | +17.8 | +21.9 | +12.7 | +41.4 | +1.2 |
| 2026 | -15.4 | +0.5 | +7.4 | +6.2 | -5.6 | +6.5 | -14.7 | +34.8 | -10.6 |



